Standard androgen deprivation therapy for prostate cancer

Nima Sharifi

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Prostate cancer is the second leading cause of cancer death for men in the United States. Tumor progression is driven by conversion of testosterone by 5a-reductase to dihydrotestosterone, which both bind and activate the androgen receptor (AR). Androgen deprivation therapy (ADT), or depletion of gonadal testosterone, blocks this sequence of events, and has been the mainstay of upfront systemic treatment for prostate cancer for 70 years. ADT is achieved by surgical or pharmacological means. Although the majority of circulating testosterone is depleted, intratumoral testosterone and dihydrotestosterone persist after ADT, implying the existence of alternative source(s) of these androgens. Importantly, the generation of intratumoral androgens and ensuing AR activation is a major mechanism that drives resistance to ADT. The goal of this review is to summarize the approaches to ADT, effects on the tumor, clinical benefits and mechanisms of resistance.

Original languageEnglish (US)
Pages (from-to)5-8
Number of pages4
JournalDrug Discovery Today: Therapeutic Strategies
Volume7
Issue number1-2
DOIs
StatePublished - Jun 2010

Fingerprint

Androgens
Prostatic Neoplasms
Testosterone
Dihydrotestosterone
Androgen Receptors
Therapeutics
Neoplasms
Cause of Death
Oxidoreductases
Pharmacology

ASJC Scopus subject areas

  • Drug Discovery
  • Pharmacology
  • Molecular Medicine

Cite this

Standard androgen deprivation therapy for prostate cancer. / Sharifi, Nima.

In: Drug Discovery Today: Therapeutic Strategies, Vol. 7, No. 1-2, 06.2010, p. 5-8.

Research output: Contribution to journalArticle

@article{8dd36759eaa8430aa3df299dd7ad1a33,
title = "Standard androgen deprivation therapy for prostate cancer",
abstract = "Prostate cancer is the second leading cause of cancer death for men in the United States. Tumor progression is driven by conversion of testosterone by 5a-reductase to dihydrotestosterone, which both bind and activate the androgen receptor (AR). Androgen deprivation therapy (ADT), or depletion of gonadal testosterone, blocks this sequence of events, and has been the mainstay of upfront systemic treatment for prostate cancer for 70 years. ADT is achieved by surgical or pharmacological means. Although the majority of circulating testosterone is depleted, intratumoral testosterone and dihydrotestosterone persist after ADT, implying the existence of alternative source(s) of these androgens. Importantly, the generation of intratumoral androgens and ensuing AR activation is a major mechanism that drives resistance to ADT. The goal of this review is to summarize the approaches to ADT, effects on the tumor, clinical benefits and mechanisms of resistance.",
author = "Nima Sharifi",
year = "2010",
month = "6",
doi = "10.1016/j.ddstr.2011.02.002",
language = "English (US)",
volume = "7",
pages = "5--8",
journal = "Drug Discovery Today: Therapeutic Strategies",
issn = "1740-6773",
publisher = "Elsevier Limited",
number = "1-2",

}

TY - JOUR

T1 - Standard androgen deprivation therapy for prostate cancer

AU - Sharifi, Nima

PY - 2010/6

Y1 - 2010/6

N2 - Prostate cancer is the second leading cause of cancer death for men in the United States. Tumor progression is driven by conversion of testosterone by 5a-reductase to dihydrotestosterone, which both bind and activate the androgen receptor (AR). Androgen deprivation therapy (ADT), or depletion of gonadal testosterone, blocks this sequence of events, and has been the mainstay of upfront systemic treatment for prostate cancer for 70 years. ADT is achieved by surgical or pharmacological means. Although the majority of circulating testosterone is depleted, intratumoral testosterone and dihydrotestosterone persist after ADT, implying the existence of alternative source(s) of these androgens. Importantly, the generation of intratumoral androgens and ensuing AR activation is a major mechanism that drives resistance to ADT. The goal of this review is to summarize the approaches to ADT, effects on the tumor, clinical benefits and mechanisms of resistance.

AB - Prostate cancer is the second leading cause of cancer death for men in the United States. Tumor progression is driven by conversion of testosterone by 5a-reductase to dihydrotestosterone, which both bind and activate the androgen receptor (AR). Androgen deprivation therapy (ADT), or depletion of gonadal testosterone, blocks this sequence of events, and has been the mainstay of upfront systemic treatment for prostate cancer for 70 years. ADT is achieved by surgical or pharmacological means. Although the majority of circulating testosterone is depleted, intratumoral testosterone and dihydrotestosterone persist after ADT, implying the existence of alternative source(s) of these androgens. Importantly, the generation of intratumoral androgens and ensuing AR activation is a major mechanism that drives resistance to ADT. The goal of this review is to summarize the approaches to ADT, effects on the tumor, clinical benefits and mechanisms of resistance.

UR - http://www.scopus.com/inward/record.url?scp=80055001129&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80055001129&partnerID=8YFLogxK

U2 - 10.1016/j.ddstr.2011.02.002

DO - 10.1016/j.ddstr.2011.02.002

M3 - Article

AN - SCOPUS:80055001129

VL - 7

SP - 5

EP - 8

JO - Drug Discovery Today: Therapeutic Strategies

JF - Drug Discovery Today: Therapeutic Strategies

SN - 1740-6773

IS - 1-2

ER -